TY - JOUR
T1 - Calcium Channel blockers are associated with reduced risk of Parkinson's disease in patients with hypertension
T2 - A population-based retrospective cohort study
AU - Tseng, Yuan Fu
AU - Lin, Hsiu Chen
AU - Chao, Jane Chen Jui
AU - Hsu, Chien Yeh
AU - Lin, Hsiu Li
N1 - Funding Information:
This study is based on data from the National Health Insurance Research Database provided by the National Health Insurance Administration and managed by the National Health Research Institutes. Our interpretations and conclusions contained herein do not represent those of the National Health Insurance Administration or the National Health Research Institutes.
Publisher Copyright:
© 2021 Elsevier B.V.
PY - 2021/5/15
Y1 - 2021/5/15
N2 - Background: The use of dihydropyridine calcium channel blockers (DCCBs) was proposed to reduce the risk of Parkinson's disease (PD). This study aimed to evaluate the association between DCCB and its dose effect and the risk of PD in patients with newly diagnosed hypertension. Methods: This population-based retrospective cohort study enrolled 107,207 patients with newly diagnosed hypertension, between 2001 and 2013, from Taiwan's National Health Insurance Research Database. Patients who had PD before hypertension or were taking antipsychotics for more than 30 days in the 6 months prior to the end of the observation period were excluded. A Cox proportional hazard model was used to estimate the risk of PD in different groups. The dose-related effects of DCCB on the risk of PD were evaluated according to the cumulative defined daily dose (DDD). Results: We observed 832 (1.2%) PD cases in patients treated with DCCB as compared to 950 (2.4%) PD cases in those not treated with DCCB, during a median follow-up duration of 8.3 years and 6.2 years, respectively. The risk of PD in the DCCB-treated group (hazard ratio [HR] = 0.50) was significantly lower than that in the group without DCCB treatment. DCCB reduced the risk of PD in a dose-dependent manner, with HRs ranging from 0.61 to 0.37 for DDDs of 90–180 to >720. Conclusions: DCCB treatment was associated with a significantly reduced risk of PD in patients with newly diagnosed hypertension. Further clinical trials are needed to confirm the proposed neuroprotective effects of DCCB in PD.
AB - Background: The use of dihydropyridine calcium channel blockers (DCCBs) was proposed to reduce the risk of Parkinson's disease (PD). This study aimed to evaluate the association between DCCB and its dose effect and the risk of PD in patients with newly diagnosed hypertension. Methods: This population-based retrospective cohort study enrolled 107,207 patients with newly diagnosed hypertension, between 2001 and 2013, from Taiwan's National Health Insurance Research Database. Patients who had PD before hypertension or were taking antipsychotics for more than 30 days in the 6 months prior to the end of the observation period were excluded. A Cox proportional hazard model was used to estimate the risk of PD in different groups. The dose-related effects of DCCB on the risk of PD were evaluated according to the cumulative defined daily dose (DDD). Results: We observed 832 (1.2%) PD cases in patients treated with DCCB as compared to 950 (2.4%) PD cases in those not treated with DCCB, during a median follow-up duration of 8.3 years and 6.2 years, respectively. The risk of PD in the DCCB-treated group (hazard ratio [HR] = 0.50) was significantly lower than that in the group without DCCB treatment. DCCB reduced the risk of PD in a dose-dependent manner, with HRs ranging from 0.61 to 0.37 for DDDs of 90–180 to >720. Conclusions: DCCB treatment was associated with a significantly reduced risk of PD in patients with newly diagnosed hypertension. Further clinical trials are needed to confirm the proposed neuroprotective effects of DCCB in PD.
KW - Calcium channel blocker
KW - Dihydropyridine
KW - Hypertension
KW - National Health Insurance Research Dataset
KW - Parkinson's disease
UR - http://www.scopus.com/inward/record.url?scp=85103409090&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85103409090&partnerID=8YFLogxK
U2 - 10.1016/j.jns.2021.117412
DO - 10.1016/j.jns.2021.117412
M3 - Article
C2 - 33799214
AN - SCOPUS:85103409090
SN - 0022-510X
VL - 424
JO - Journal of the Neurological Sciences
JF - Journal of the Neurological Sciences
M1 - 117412
ER -